Neil R Mathias

US Patent:

20120053130, Mar 1, 2012

Filed:

Aug 30, 2010

Appl. No.:

12/871460

Inventors:

Neil R. Mathias - North Brunswick NJ, US
Lianli Li - Pomona NY, US

International Classification:

A61K 38/12
A61K 31/522
A61K 31/165

US Classification:

514 211, 514620, 51426337

Abstract:

A composition for enhancing absorption of a pharmaceutical which may have poor oral bioavailability, which composition has surprisingly little cytotoxicity, is provided which is in the form of a liquid or semi-solid or solid containing an admixture (1) a mucoadhesive polymer which is a polyacrylic acid polymer, preferably Carbopol 971P, and (2) an absorption or permeation enhancer which preferably is L-α-lyso-phosphatidylcholine (LPC), and which composition is free of polysaccharides. A method for improving bioavailability of a drug which has poor absorption properties is also provided wherein the above bioadhesive composition is administered with said pharmaceutical to the mucosal membrane of the GI tract, nose, oral cavity, sublingual, buccal, and vaginal mucosa.A method for reducing the cytotoxic effect of an absorption enhancer such as LPC is also provided wherein a mucoadhesive polymer as described above is administered with the LPC to a patient in need of treatment.

US Patent:

20050244502, Nov 3, 2005

Filed:

Apr 25, 2005

Appl. No.:

11/113839

Inventors:

Neil Mathias - North Brunswick NJ, US
Lianli Li - Pomona NY, US

International Classification:

A61K009/14

US Classification:

424487000

Abstract:

A composition for enhancing absorption of a pharmaceutical which may have poor oral bioavailability, which composition has surprisingly little cytotoxicity, is provided which is in the form of a liquid or semi-solid or solid containing an admixture (1) a mucoadhesive polymer which is a polyacrylic acid polymer, preferably Carbopol 971P, and (2) an absorption or permeation enhancer which preferably is L-α-lyso-phosphatidylcholine (LPC), and which composition is free of polysaccharides. A method for improving bioavailability of a drug which has poor absorption properties is also provided wherein the above bioadhesive composition is administered with said pharmaceutical to the mucosal membrane of the GI tract, nose, oral cavity, sublingual, buccal, and vaginal mucosa. A method for reducing the cytotoxic effect of an absorption enhancer such as LPC is also provided wherein a mucoadhesive polymer as described above is administered with the LPC to a patient in need of treatment.

US Patent:

20160305922, Oct 20, 2016

Filed:

Apr 14, 2016

Appl. No.:

15/098514

Inventors:

- Billerica MA, US
Dan Tang - Brooklyn NY, US
Scott P. Jennings - Bridgewater NJ, US
Neil Mathias - North Brunswick NJ, US
Konstantin L. Tsinman - Littleton MA, US
Deren J. Dohoda - Billerica MA, US
David A. Kwajewski - Wilbraham MA, US
Michael G. Kelly - Waltham MA, US

International Classification:

G01N 33/15
G01N 15/08

Abstract:

An apparatus for the combined assessment of dissolution and permeability relies on a receiver chamber that is contained within a donor chamber. A membrane is provided between the two chambers. Measurements can be taken to determine solute amounts of a drug introduced in the donor chamber and amounts of permeated solute in the receiver chamber. Also described are techniques for the assessment of a dissolution rate and total amount of dissolved compound, together with their effect on absorption potential of a compound or a compound product as well as approaches for evaluating in vivo relevant differences between formulations of a compound through their effect on the absorption potential of the compound.